Immuron Ltd — AGM Information 2025

Nov 10, 2025

==> picture [200 x 50] intentionally omitted <==

ASX/NASDAQ Announcement

11 November 2025

2025 Annual General Meeting - CEO Address

Immuron Limited (ASX: IMC; NASDAQ: IMRN) attaches the CEO Address to be delivered by Chief Executive Officer, Steve Lydeamore, at this morning’s Annual General Meeting.

• • • END - - -

This release has been authorised by the Directors of Immuron Limited.

Further information

Steven Lydeamore

Chief Executive Officer steve@immuron.com

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

Immuron Platform Technology

Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyperimmune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of

==> picture [567 x 65] intentionally omitted <==

medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com Sign up to Immuron’s Investor Hub: Here

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

==> picture [567 x 65] intentionally omitted <==

==> picture [419 x 419] intentionally omitted <==

==> picture [197 x 48] intentionally omitted <==

AGM PRESENTATION 11 NOVEMBER 2025 Steven Lydeamore - CEO NASDAQ: IMRN ASX: IMC

SAFE HARBOR STATEMENT

Certain statements made in this presentation are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

FY2026 results in this presentation are subject to audit review.

==> picture [132 x 32] intentionally omitted <==

----- Start of picture text -----

2
----- End of picture text -----

2

==> picture [216 x 34] intentionally omitted <==

==> picture [55 x 53] intentionally omitted <==

Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases

Technology Platform

Research & Platform Development Safe and potentially transformational 3 pipeline assets in 2 approach to gut clinical programmes infections

Our Products

==> picture [272 x 35] intentionally omitted <==

Global footprint Australia, US, Canada and expanding

Corporate Research Independent Buy recommendation

==> picture [69 x 37] intentionally omitted <==

----- Start of picture text -----

NEW
----- End of picture text -----

==> picture [269 x 36] intentionally omitted <==

Technology Platform

• Proprietary technology based on generating hyper-immune bovine colostrum that is rich in polyclonal antibodies also known as immunoglobulins.

• Bovine antibodies also possess the unique ability to remain active in the human GI tract where they target enteric pathogens.

• The underlying nature of our platform technology enables the development of medicines across a large range of infectious diseases.

• Reduce the risk of Traveller’s Diarrhoea

• Sold in pharmacies Australia-wide

• Available in Australia, USA and Canada

• Treatment of symptoms associated with Irritable Bowel Syndrome (IBS)

• • To be sold in pharmacies Australia-wide • Available in Australia

• The platform can be used to generate bovine antibodies that block viruses or bacteria at mucosal surfaces in the Gastrointestinal tract and neutralize the toxins they produce.

3

FY25 Financial Achievements

==> picture [505 x 292] intentionally omitted <==

----- Start of picture text -----

Global Sales Australian Sales
Revenue Revenue
$7.3m $5.3m
Up 49% Up 40%
EBITDA (ex-R&D) [1]
Gross Profit
$(3.1)m
Margin
$2.1m
65.4%
improvement
----- End of picture text -----

==> picture [205 x 292] intentionally omitted <==

----- Start of picture text -----

North American
Sales Revenue
$2.0m
Up 76%
Cash + Term
Deposit [ 2,3]
$5.9m
----- End of picture text -----

• 1 ex-R&D: add back research & development, less R&D Tax Incentive and R&D grants; 2 30 June 2025, as reported in Immuron’s Appendix 4E (Cash $2.83m; Term Deposit $3.04m); 3 Since 30 June 2025, Immuron has raised, cost-effectively, A$3.55m from the US At-The-Market facility.

==> picture [87 x 21] intentionally omitted <==

8

Travelan® continued strong sales growth

Global

• FY2025 AUD$7.3 million up 49% on prior year

• FY2026 Q1 AUD$2.0 million up 34% on FY2025 Q1

Australia

• FY2025 AUD$5.2 million up 40% on prior year + FY2026 AUD$1.6 million up 52% on FY2025 Q1

North America

• • FY2025 AUD$2.0 million up 76% on prior year + FY2026 AUD$0.4 million down 8% on FY2025 Q1 + USA FY2026 AUD$0.4 million up 44% on FY2026 Q1

==> picture [465 x 427] intentionally omitted <==

----- Start of picture text -----

Global Year to Date Net Sales ($AUD)
$8,000,000
$7,000,000
$6,000,000
$5,000,000
$4,000,000
$3,000,000
$2,000,000
$1,000,000
FY24 FY25
$-
Jul - Sep Oct - Dec Jan - Mar Apr - Jun
$8,000,000
$7,000,000
$6,000,000
$5,000,000
$4,000,000 North America
Australia
$3,000,000
$2,000,000
$1,000,000
$-
FY22 FY23 FY24 FY25
----- End of picture text -----

==> picture [87 x 21] intentionally omitted <==

5

FY25 Clinical Achievements and Operational Highlights

==> picture [826 x 334] intentionally omitted <==

----- Start of picture text -----

Travelan® Ph 2
FDA approval Travelan®
statistically
IMM-529 n=851 trial
significant
IND completed
results [1]
Updated peak
New research New product
U.S. sales for
collaboration launch in
IMM-529
IMM-986 (VRE) Australia
US$400 million [2]
----- End of picture text -----

1. Immunology results and Microbiome responses; 2. Lumanity global healthcare consulting

==> picture [87 x 21] intentionally omitted <==

6

FY26 Outlook

==> picture [822 x 334] intentionally omitted <==

----- Start of picture text -----

Progression Travelan®
Continued YoY towards EBITDA
n=851 trial topline
sales growth (ex-R&D) [1 ] data
breakeven November 2025
Travelan®
IMM-529 IMM-986 (VRE)
End of Phase 2
Initiation of Phase 2 Pre-clinical data
Meeting with FDA
1H 2026 1H 2026
1H 2026
1 ex-R&D: add back research & development, less R&D Tax Incentive and R&D grants
----- End of picture text -----

1 ex-R&D: add back research & development, less R&D Tax Incentive and R&D grants

==> picture [87 x 21] intentionally omitted <==

7

==> picture [419 x 419] intentionally omitted <==

==> picture [175 x 43] intentionally omitted <==

STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED

CONTACT INFORMATION:

EMAIL: STEVE@IMMURON.COM

PHONE: AUSTRALIA: +61 438 027 172

IMMURON INVESTOR HUB

==> picture [55 x 53] intentionally omitted <==

COMMUNICATION AND CONTENT INCLUDING ANNOUNCEMENTS AND CORPORATE RESEARCH